UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report: May 23, 2008
--------------------------------------------------------------------------------
(Date of earliest event reported)
ABIOMED, Inc.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 04-2743260
(State or other Jurisdiction (IRS Employer
of Incorporation) Identification Number)
0-20584
(Commission File Number)
22 Cherry Hill Drive
Danvers, MA 01923
(Address of Principal Executive Offices, including Zip Code)
(978) 646-1400
(Registrant's Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
| | Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
| | Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
| | Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
| | Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)
--------------------------------------------------------------------------------
================================================================================
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) On May 23, 2008, our compensation committee made its annual
compensation determinations for our executive officers. The committee determined
the bonuses for fiscal 2008 performance, the salaries for fiscal 2009 and made
the annual equity grants to executive officers. The compensation decisions made
with respect to our executive officers who were named executive officers in our
most recent proxy statement were as follows:
Shares Restricted
Fiscal Fiscal Underlying Restricted Stock
2008 2009 Stock Options Stock (Performance
Executive Officer Bonus Salary (4 year vesting) (4 year vesting) vesting)
--------------------------------- ---------- ---------- ----------------- ----------------- ----------------
Michael R. Minogue, $354,000 $371,700 43,333 43,333 43,334
Chairman, CEO and President
Daniel J. Sutherby, Chief $75,000 $236,385 10,000 9,000 6,000
Financial Officer
Andrew J. Greenfield, Vice $75,000 $194,555 9,000 10,000 11,000
President Healthcare Solutions
================================================================================
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Abiomed, Inc.
By: /s/ Daniel J. Sutherby
-------------------------
Daniel J. Sutherby
Chief Financial Officer
Date: May 30, 2008